RecruitingNCT03616483

The Indiana Myeloma Registry

Collection of Specimens and Clinical Data to Create A Bio-repository for the Multiple Myeloma Program: The Indiana Myeloma Registry


Sponsor

Indiana University

Enrollment

2,500 participants

Start Date

Jun 18, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a patient registry (a database of real-world patient information) at Indiana University tracking people with multiple myeloma or related blood disorders, to better understand how these conditions progress and respond to treatment over time. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with, or are suspected of having, one of the following: - Monoclonal Gammopathy of Undetermined Significance (MGUS, an early stage condition where abnormal proteins appear in the blood) - Smoldering Multiple Myeloma (an early, slow-growing form) - Multiple Myeloma - Plasmacytoma (a tumor made of abnormal plasma cells) - Primary Amyloidosis (a condition where abnormal proteins build up in organs) **You may NOT be eligible if...** - You are under 18 years old - You have not been diagnosed with one of the conditions listed above Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERThis is a non-interventional trial

This is a non-interventional trial


Locations(1)

Indiana University Simon Cancer Center

Indianapolis, Indiana, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03616483


Related Trials